Phd in ENDOCRINOLOGICAL SCIENCES

Research: Characterization of the Platelet Profile in Patients with Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD)

Education and Training PhD in Endocrinological Sciences – Sapienza University of Rome Rome, Italy | 2022 – ongoing Research project focused on the functional characterization of platelets in chronic liver diseases (NAFLD, NASH, cirrhosis) and their interaction with the immune system. Specialization in Allergy and Clinical Immunology – Sapienza University of Rome, Rome, Italy | 2018 – 2021 Master’s Degree in Medicine and Surgery – Sapienza University of Rome Rome, Italy | 2010 – 2016 Medical License Medical Board of the Province of Foggia | 2017 Work Experience Teaching activities for Medical Degree Programs and Master’s Programs Research Fellow – Sapienza University of Rome, Department of Translational and Precision Medicine 2022: Planning of patient recruitment for studies on early biomarkers of thromboinflammation in patients with pneumonia. Study Investigator – Clinical trial MK-3655 for NASH (sponsored by MSD) Study Coordinator – Phase III Librexia ACS trial (Janssen Research & Development) Study Investigator – THARROS clinical trial (AstraZeneca) Clinical practice in Allergy and Clinical Immunology Scientific and Clinical Skills Clinical and translational research Thromboinflammation pathogenesis Metabolic liver diseases (NAFLD/NASH) Clinical immunology and allergology Clinical trial management and coordination Clinical and biomedical data analysis Research database management Languages Italian: Native speaker English: C1 (Reading C2) Research Project The PhD research project focuses on the role of platelets as mediators of thromboinflammation in metabolic chronic liver diseases (NAFLD, NASH and cirrhosis). Main objectives: characterize functional platelet alterations in patients with metabolic liver disease investigate the interaction between platelets and innate and adaptive immune cells identify potential biomarkers of inflammation and disease progression contribute to the development of therapeutic strategies targeting thrombo-inflammatory mechanisms Patents / Clinical Trials Participation in international multicenter clinical trials, including: MK-3655 trial for patients with NASH (MSD) Librexia ACS – Phase III trial on milvexian after acute coronary syndrome (Janssen) THARROS trial on triple inhaled therapy in patients with COPD (AstraZeneca) Roles: Study Investigator and Study Coordinator Publications and Abstracts - Di Cola et al., «Platelets from patients with decompensated cirrhosis display pro-inflammatory features»; - Floridia et al., «Persisting or recurrent dermatological manifestations in Long-COVID: Data from a national cohort of 1741 patients from Italy»; - Asero et al., «Peanut allergy in Italy: A unique Italian perspective»; - Lombardi et al., «PB0802 Platelet Features that Identify Early Stages of Liver Disease Progression»; - Pallucci et al., «PB0772 Platelet-B Cell Interactions Modulate the Antibody Response to Adenoviral and mRNA Vaccines against SARS-CoV-2»; - La Gualana et al., «Opposite effects of mrna-based and adenovirus-vectored SARS-CoV-2 vaccines on regulatory t cells: A pilot study»; - D’Amico et al., «Neutrophil–lymphocyte ratio is associated with worse outcomes in patients with cirrhosis: insights from the PRO-LIVER Registry»; - Scala et al., «Mollusk allergy in shrimp-allergic patients: Still a complex diagnosis. An Italian real-life cross-sectional multicenter study»; - Vantaggio et al., «Might IgA be a Biomarker of Disease Activity in Takayasu Arteritis?»; - Pecani et al., «Metabolic syndrome and liver disease: re-appraisal of screening, diagnosis, and treatment through the paradigm shift from NAFLD to MASLD»; - Pellicano et al., «Maresin1 is a predictive marker of new digital ulcers in systemic sclerosis patients»; - Cangemi et al., «Infections as predictors of NAFLD progression»; - Pellicano et al., «Increased complement activation in systemic sclerosis patients with skin and lung fibrosis»; - MIGLIONICO et al., «IL RISCHIO CARDIOVASCOLARE: DIFFERENZE DI SESSO E GENERE»; - Visentini et al., «High prevalence of past hepatitis B virus infection in diffuse large B cell lymphoma: a retrospective study from Italy»; - Andreozzi et al., «Heated tobacco products vs conventional cigarettes: a scoping review of cardiovascular and respiratory clinical outcomes»; - Pulvirenti et al., «Health-related quality of life in common variable immunodeficiency Italian patients switched to remote assistance during the COVID-19 pandemic»; - Liguori et al., «FREE LIGHT CHAINS: A NEW POTENTIAL BIOMARKER FOR DISEASE STRATIFICATION IN NON-ALCOHOLIC STEATOHEPATITIS»; - Pecani et al., «Exploring the relationship between metabolic dysfunction-associated steatotic liver disease and osteoporosis»; - Basili et al., «Exploring additional strategy to improving cognitive skills in older adults»; - Miglionico et al., «Distinct platelet phenotype and reactivity in individuals with permanent atrial fibrillation treated with direct oral anticoagulants: a pilot study»; - Lombardi et al., «Distinct platelet crosstalk with adaptive and innate immune cells after adenoviral and mRNA vaccination against SARS-CoV-2»; - Quinti et al., «Differential Diagnostic in Cellular Immunodeficiencies»; - Raparelli et al., «Changes of in-vivo markers of platelet activation during the menstrual cycle in healthy pre-menopausal female individuals»; - Maiorca et al., «Breakthrough infections after COVID-19 vaccinations do not elicit platelet hyperactivation and are associated with high platelet–lymphocyte and low platelet–neutrophil aggregates»; - Pellicano et al., «Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis»; - Cicero et al., An age-independent MASLD-related liver fibrosis index reflecting gut dysbiosis and hepatic stellate cells reprogramming; - Cangemi et al., «Adherence to the Mediterranean Diet in Preventing Major Cardiovascular Events in Patients with Ischemic Heart Disease: The EVA Study»; - Zampieri et al., «A potential age-independent MASLD-related liver fibrosis index based on metabolic profiling».